Lamanna, Nicole <br/><br/>
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Feb 2009 
 - 491-7 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2008.16.4459  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Agents, Alkylating--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Cyclophosphamide--administration & dosage<br/>Drug Administration Schedule<br/>Female<br/>Flow Cytometry<br/>Follow-Up Studies<br/>Humans<br/>Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Polymerase Chain Reaction<br/>Remission Induction<br/>Rituximab<br/>Vidarabine--administration & dosage